<DOC>
	<DOCNO>NCT00084747</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes necessary growth . Giving bortezomib maintenance therapy autologous stem cell transplantation may kill cancer cell prolong remission . PURPOSE : This phase I/II trial study side effect best dose adjuvant bortezomib maintenance therapy see well work treat patient undergone stem cell transplantation intermediate advance multiple myeloma .</brief_summary>
	<brief_title>Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation Treating Patients With Intermediate Advanced Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate , define resolution bone marrow plasmacytosis monoclonal paraproteinemia , first year autologous peripheral blood stem cell transplantation patient intermediate advanced multiple myeloma treat adjuvant bortezomib . - Compare progression-free survival patient treat adjuvant bortezomib historical control treat autologous transplantation alone . - Determine toxicity drug patient ( phase I ) . OUTLINE : This multicenter , dose-escalation study . Patients receive bortezomib IV day 1 , 8 , 15 . Treatment repeat every 28 day 8 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 3-30 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Diagnosis intermediate advance multiple myeloma meeting criterion least 1 2 following : Intermediate highMcomponent production rate ( immunoglobulin [ Ig ] G &gt; 5 g/dL immunoglobulin A ( IgA ) &gt; 3 g/dL urine M component &gt; 4 g/24 hour ) More one osteolytic bone lesion radiographic evidence diffuse osteoporosis β2 microglobulin &gt; 3 Nonsecretory myeloma bone marrow plasmacytosis great 30 % Must undergone autologous peripheral blood stem cell transplantation within past 34 month Age 18 69 year old Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 30,000/mm^3 serum glutamate oxaloacetate transaminase ( SGOT ) serum glutamate pyruvate transaminase ( SGPT ) ≤ 300 IU Bilirubin ≤ 2 mg/dL Creatinine ≤ 2.0 mg/dL Creatinine clearance ≥ 30 mL/min Negative pregnancy test Fertile patient must use effective contraception concurrent major cardiac disease would preclude study participation concurrent major pulmonary disease would preclude study participation pregnant nursing peripheral neuropathy ≥ grade 2 history hypersensitivity bortezomib , boron , mannitol concurrent major gastrointestinal bladder disease would preclude study participation concurrent major neurologic psychiatric disease would preclude study participation dementia significantly alter mental status would preclude give informed consent prior interferon posttransplantation prior thalidomide posttransplantation prior chemotherapy posttransplantation prior radiotherapy posttransplantation prior investigational therapy posttransplantation prior bortezomib prior therapy myeloma posttransplantation concurrent antimyeloma therapy concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>